A Research Guide for
Anal Cancer

HPV is an extremely common virus — most sexually active adults will be exposed at some point. In the vast majority of people, the immune system clears the infection without consequences. In a small percentage, persistent infection with high-risk HPV types (especially HPV-16) leads to progressive cellular changes: from normal tissue to low-grade precancerous changes (LSIL/AIN 1), to high-grade precancerous changes (HSIL/AIN 2-3), and eventually to invasive cancer. This process typically takes years to decades.

It is important to state clearly: an HPV-related cancer diagnosis is not a moral judgment. HPV is nearly ubiquitous — the CDC estimates that nearly all sexually active people will acquire HPV at some point. The virus can persist silently for decades before causing disease. Having anal cancer does not imply any particular behavior, and patients should not carry shame about their diagnosis. The medical team treats the cancer, not the circumstances of its origin.

Ask: "Is my cancer HPV-related, and should my eligible family members get the HPV vaccine to lower their own risk?" HPV status is useful prognostic information, and vaccination (Gardasil 9) can protect the people around you.

The HPV vaccine (Gardasil 9) prevents infection with the HPV types that cause the vast majority of anal cancers. Vaccination is most effective when given before HPV exposure, but it can provide benefit even in adults who have already been exposed. The CDC recommends HPV vaccination for all individuals through age 26, and shared clinical decision-making for adults aged 27–45. Studies are examining HPV vaccination strategies for adults already at risk (verify current trials on ClinicalTrials.gov).

HPV vaccination is one of the most effective cancer prevention tools available. Parents should discuss vaccination with their children’s pediatrician.

Screening for anal precancer and early cancer is recommended for high-risk groups. The landmark ANCHOR trial (NCT02135419) demonstrated that treating high-grade anal squamous intraepithelial lesions (HSIL) in people living with HIV reduced progression to anal cancer by 57%, establishing screening and treatment of precancerous lesions as effective cancer prevention.

Groups recommended for screening include:

• People living with HIV
• Men who have sex with men (regardless of HIV status)
• Women with history of cervical, vulvar, or vaginal cancer or high-grade dysplasia
• Solid organ transplant recipients
• Other immunosuppressed individuals

Screening typically begins with an anal Pap smear (anal cytology). Abnormal results are followed by high-resolution anoscopy (HRA) — a procedure similar to colposcopy that allows the examiner to identify and biopsy suspicious areas in the anal canal.

When evaluating any treatment claim for anal cancer, ask these questions:

• Is it supported by published clinical trial data in peer-reviewed journals?
• Is it consistent with NCCN or ESMO guidelines?
• Could it delay or interfere with chemoradiation, which is the proven curative treatment?
• Does anyone with no financial stake in it recommend it?
• Are the doctors at major cancer centers using it?

Be especially cautious of anyone who suggests replacing standard chemoradiation with alternative approaches. Chemoradiation has decades of evidence showing it cures most anal cancers. Delays or replacements can allow the disease to progress to a point where a permanent colostomy becomes necessary.

• Bring a second person to every appointment. One listens; the other writes things down.
• Ask permission to record. Most clinics allow phone recording if asked first.
• Keep a single folder with all reports: biopsy pathology, imaging, blood work, and treatment records.
• Be honest about your complete medical history, including HIV status, sexual health history, and any prior HPV-related conditions. This is essential information for treatment planning and is treated confidentially.

• ☐ Diagnosis confirmed on biopsy — squamous cell carcinoma vs. other type
• ☐ HIV testing completed (required for all patients)
• ☐ HPV and p16 immunohistochemistry status noted on pathology
• ☐ Staging workup ordered: CT chest/abdomen/pelvis, pelvic MRI, PET-CT
• ☐ Examination under anesthesia (EUA) performed or scheduled for precise tumor assessment
• ☐ Digital rectal examination documented tumor size, location, and sphincter involvement
• ☐ For women: gynecologic evaluation for concurrent HPV-related cervical/vulvar disease
• ☐ Treating center identified — confirm anal cancer-specific radiation and surgical experience
• ☐ Radiation oncologist and medical oncologist appointments scheduled
• ☐ Records folder started: pathology, imaging, labs in one place
• ☐ If HIV-positive: HIV care team informed and antiretroviral therapy optimized

Anal cancer is treatable, and the early steps are about getting an accurate stage and a well-designed radiation plan — not rushing. Use this timeline as a calendar.

• In the first 48 hours: start a single records folder (pathology, imaging, labs); write down your questions; bring a second person to appointments.
• Within the first week: confirm the biopsy report says squamous cell carcinoma (not adenocarcinoma, which is treated differently); make sure HIV testing has been ordered; confirm p16/HPV status is noted.
• Within two weeks: complete staging — pelvic MRI, CT of the chest/abdomen/pelvis, and PET-CT; meet both a radiation oncologist and a medical oncologist at a center that treats anal cancer regularly.
• In the first month: have a defined chemoradiation start date and written confirmation the plan uses IMRT with 5-FU (or capecitabine) plus mitomycin C.

Then comes the part that requires patience: after chemoradiation ends, the tumor shrinks slowly. The first response check is usually at 8–12 weeks, and a complete response can take up to about 26 weeks (roughly 6 months). Regression continuing for months is normal and expected — rushing to salvage surgery before the tumor has had time to fully respond can lead to an unnecessary permanent colostomy. Ask: "If my tumor is shrinking but not gone at the first check, how long will you wait and watch before considering surgery?"

• Digital rectal examination (DRE): The most important initial assessment. Documents tumor size, location, distance from the anal verge, relationship to the sphincter muscles, and clinical lymph node involvement.
• Examination under anesthesia (EUA): Allows thorough assessment of the tumor and biopsies under optimal conditions.
• Pelvic MRI: Provides detailed imaging of the primary tumor and pelvic lymph nodes. Critical for radiation planning.
• CT of the chest, abdomen, and pelvis: Screens for distant metastases, particularly to the liver and lungs.
• PET-CT: Increasingly used and recommended by NCCN. Can detect lymph node involvement and distant disease not seen on CT alone. Particularly valuable for accurate radiation field design.
• Inguinal lymph node assessment: Physical examination of the groin lymph nodes. Fine-needle aspiration biopsy of any suspicious inguinal nodes.

Anal cancer uses the TNM staging system:

• T (Tumor size): T1 (≤2 cm), T2 (2–5 cm), T3 (>5 cm), T4 (invading adjacent organs such as the vagina, urethra, or bladder).
• N (Nodes): N0 (no lymph node involvement), N1 (spread to inguinal, mesorectal, or internal iliac lymph nodes).
• M (Metastasis): M0 (no distant spread) or M1 (distant metastases).

Overall stages: Stage I (T1 N0), Stage IIA (T2 N0), Stage IIB (T3 N0), Stage IIIA (T1-2 N1), Stage IIIB (T3-4 N1), Stage IIIC (T4 N0), Stage IV (any M1).

• Radiation oncologists experienced in intensity-modulated radiation therapy (IMRT) for anal cancer
• A multidisciplinary tumor board that includes radiation oncology, medical oncology, and colorectal surgery
• Colorectal surgeons experienced in salvage abdominoperineal resection
• Access to immunotherapy and clinical trials for advanced disease
• Supportive care services: dermatology for radiation skin toxicity, sexual health counseling, ostomy support if needed

A second opinion is valuable for any anal cancer diagnosis, particularly for locally advanced disease (T3-4 or node-positive) or recurrent disease where salvage surgery may be considered. Major centers offer remote second-opinion programs. The radiation treatment plan should ideally be reviewed by a radiation oncologist with specific anal cancer expertise.

The standard regimen combines:

• Radiation therapy: Typically 50.4–59 Gy delivered over 5–6 weeks using intensity-modulated radiation therapy (IMRT). IMRT is the current standard technique because it delivers high doses to the tumor while sparing surrounding normal tissues, reducing side effects compared to older radiation approaches.
• 5-Fluorouracil (5-FU): Given as a continuous intravenous infusion during weeks 1 and 5 of radiation (or as oral capecitabine as an alternative).
• Mitomycin C: Given as a single intravenous dose on day 1 of radiation (and sometimes day 29). This drug adds toxicity but improves cure rates compared to 5-FU alone.

Treatment typically takes about 5–6 weeks. The radiation targets the primary tumor, the draining lymph nodes in the pelvis, and the inguinal (groin) lymph nodes.

You do not need to memorize these, but knowing the standard numbers helps you confirm your plan matches the evidence-based regimen. These are the doses in the NCCN Anal Carcinoma Guidelines and the FDA prescribing information; your exact doses are individualized by your team and adjusted for your blood counts and kidney function.

• 5-Fluorouracil (5-FU): about 1000 mg/m² per day as a continuous IV infusion, usually days 1–4 and again days 29–32 (two 4-day infusions during radiation). (per NCCN; RTOG chemoradiation schedule)
• Mitomycin C: about 10–12 mg/m² given IV on day 1, sometimes repeated on day 29. (per NCCN; FDA label)
• Capecitabine (the oral alternative to 5-FU): about 825 mg/m² by mouth twice daily on the days you receive radiation. (per NCCN; FDA label)
• Radiation: approximately 50.4–59 Gy total, delivered with IMRT over about 5–6 weeks (dose set by tumor and node stage). (per NCCN; RTOG 0529)

Ask: "Can you confirm my regimen is 5-FU (or capecitabine) plus mitomycin C with IMRT, and tell me the doses you are planning?" A plan that leaves out mitomycin C, or substitutes cisplatin for it in the up-front curative setting, is a departure from the standard worth asking about.

Chemoradiation for anal cancer is an effective treatment, but it causes significant side effects, particularly during and in the weeks after treatment:

• Radiation dermatitis: Skin irritation, redness, and breakdown in the treatment area (perineum, groin). This is the most common and distressing acute side effect. It peaks in the weeks after treatment and gradually heals.
• Diarrhea: Common during and after treatment. Managed with medications and dietary adjustments.
• Fatigue: Typically worsens through treatment and can persist for weeks to months afterward.
• Nausea: Usually manageable with anti-nausea medications.
• Myelosuppression: Low blood counts from chemotherapy, particularly from mitomycin C. Blood counts are monitored regularly.
• Late effects: Some patients experience long-term changes in bowel function, sexual function, or skin integrity. These are discussed in the supportive care section.

Most acute side effects resolve within 4–8 weeks after treatment ends. The radiation oncology team should provide detailed skin care instructions and supportive medications throughout treatment.

Capecitabine, an oral fluoropyrimidine, can be used instead of intravenous 5-FU during chemoradiation. This avoids the need for a central venous catheter and continuous infusion, which many patients prefer. Clinical data, including the ACT II trial, support capecitabine as a reasonable alternative, and it is included in NCCN guidelines.

• 5-Fluorouracil (5-FU): about 1000 mg/m² per day as a continuous IV infusion, typically over 4 days (days 1–4) and repeated over 4 days near the end (days 29–32). Because it runs continuously, it is usually delivered through a small pump attached to a central line. (dose per NCCN; schedule from the RTOG 98-11 trial, NCT00003596)
• Mitomycin C: about 10 to 12 mg/m² given as a single IV dose on day 1, and sometimes repeated on day 29. Most centers cap a single dose near 20 mg. This is the drug that makes the treatment work better than radiation alone — it is not optional in standard curative care. (per NCCN; FDA label; ACT II trial)
• Capecitabine (the oral pill alternative to infused 5-FU): about 825 mg/m² by mouth twice daily on the days you receive radiation. It spares you the pump and central line. (per NCCN; supported by the ACT II trial)

Ask: "Can you confirm my regimen is 5-FU (or capecitabine) plus mitomycin C, and tell me the exact milligrams you are planning for each?”

A stop rule worth knowing. Mitomycin C can rarely cause a serious blood-and-kidney condition called hemolytic-uremic syndrome. If it is suspected, the standard is to discontinue mitomycin permanently and not re-challenge — this is a hard stop rule, not a dose adjustment. Ask: "What blood tests will you check before each mitomycin dose, and what numbers would make you hold or stop it?”

Radiation is measured in units called Gray (Gy). The standard total dose is approximately 50.4 Gy for smaller node-negative tumors and up to about 54–59 Gy for larger or node-positive tumors, delivered in small daily fractions of about 1.8 Gy over roughly 5 to 6 weeks using intensity-modulated radiation therapy (IMRT). IMRT shapes the beams to spare healthy skin and bowel. (per NCCN; dose-painting technique from the RTOG 0529 trial, NCT00423293)

Ask: "Will you use IMRT, what total Gray dose are you planning, and will my groin (inguinal) lymph nodes be included in the field?”

These do not treat the cancer, but they make the curative treatment tolerable. Knowing the names helps you ask for them if a symptom is not controlled.

• Nausea: ondansetron (Zofran) 8 mg, often with dexamethasone 4 to 12 mg; prochlorperazine 10 mg or metoclopramide 10 mg as backups. (per NCCN Antiemesis Guidelines)
• Diarrhea: loperamide (Imodium), commonly a 4 mg starting dose then 2 mg after each loose stool, up to a daily limit your team sets.
• Low white-blood-cell counts: a growth-factor shot such as filgrastim (about 5 mcg/kg per day) may be used if counts drop dangerously. (per ASCO growth-factor guidance)
• Pain and skin: barrier creams, sitz baths, and pain medicines; some patients need gabapentin 300 mg for nerve-type perineal pain.

Ask your nurse: "What is my as-needed plan — the exact medicine and dose — if the nausea or diarrhea breaks through at home, and at what point should I call instead of taking another dose?”

These are used only if the cancer is inoperable, recurrent, or has spread — not for standard curable disease.

• Carboplatin + paclitaxel + retifanlimab — the current first-line standard for fit patients. Paclitaxel is about 80 mg/m² on days 1, 8, and 15; carboplatin is dosed to a target called AUC 5; and retifanlimab (Zynyz) is 500 mg every 4 weeks (or 375 mg every 3 weeks). (FDA label, approved May 2025, based on the POD1UM-303 / InterAACT 2 trial, NCT04472429; Incyte)
• Cisplatin + 5-FU — an older backbone: cisplatin about 60 mg/m² with 5-FU about 1000 mg/m² per day. Now generally second choice because carboplatin/paclitaxel is better tolerated. (InterAACT trial)
• Modified DCF (docetaxel, cisplatin, 5-FU) — docetaxel about 40 mg/m², cisplatin about 40 mg/m², and 5-FU about 1200 mg/m² per day; an intensive option studied in the Epitopes-HPV02 trial (NCT02402842).

Ask: "For my metastatic disease, am I a candidate for carboplatin, paclitaxel, and retifanlimab together, and if not, exactly why not?”

• Retifanlimab (Zynyz): 500 mg IV every 4 weeks (or 375 mg every 3 weeks), also approved as a single agent if platinum chemotherapy stops working. (FDA label; POD1UM-202 trial, NCT03597295)
• Nivolumab (Opdivo): commonly 240 mg every 2 weeks or 480 mg every 4 weeks (earlier studies used 3 mg/kg). Guideline-supported, based on the NCI-9673 study (NCT02314169). (NCCN; not an anal-cancer-specific FDA label)
• Pembrolizumab (Keytruda): 200 mg every 3 weeks or 400 mg every 6 weeks, for tumors that are MSI-high or TMB-high under its tumor-agnostic approval. (KEYNOTE-158 trial, NCT02628067)

A stop rule for immunotherapy. These drugs can make the immune system attack healthy organs. The standard is to hold the drug for moderate reactions and to permanently discontinue if a severe (grade 3–4) immune reaction occurs — the main exception being a hormone problem that can be controlled with replacement pills. Ask: "What new symptoms should make me call you the same day, and which ones would mean stopping the immunotherapy for good?”

• Chemotherapy makes radiation work better (radiosensitization). 5-FU and mitomycin C do not just add their own effect — they make the cancer cells more vulnerable to radiation. This synergy is why chemoradiation cures most anal cancers while radiation alone historically did not. Dropping the chemotherapy sacrifices this synergistic benefit.
• Mitomycin C amplifies the cure, not just the toxicity. Adding mitomycin to 5-FU plus radiation improved colostomy-free survival in randomized trials. It is the synergy — not either drug alone — that preserves your sphincter.
• Chemotherapy plus immunotherapy in advanced disease. In the metastatic setting, the POD1UM-303 trial showed that adding the immunotherapy retifanlimab to carboplatin-paclitaxel chemotherapy produced a combined benefit beyond chemotherapy alone — the chemotherapy exposes tumor targets while the immunotherapy unleashes the immune response against them.

Ask: "Because these treatments work together, what is your plan to keep me on schedule so I get the full synergistic benefit, even if side effects flare?”

For very small tumors (T1 N0, ≤2 cm) of the anal margin (the skin surrounding the anus, not the anal canal), local excision alone may be sufficient if the tumor can be removed with clear margins and the sphincter is not involved. This is an exception to the general rule that chemoradiation is the primary treatment.

For T1 tumors of the anal canal itself, chemoradiation remains the standard approach, though the radiation dose may be somewhat lower than for larger tumors.

People living with HIV develop anal cancer at higher rates, and there has historically been concern about treatment tolerance. Current evidence shows that HIV-positive patients on effective antiretroviral therapy can and should receive full-dose chemoradiation with curative intent. CD4 counts should be monitored, and antiretroviral therapy should be optimized before and during treatment. Close coordination between the oncology and HIV care teams is essential. HIV infection is not a reason to reduce treatment intensity.

After chemoradiation, the tumor does not disappear immediately. Regression is gradual and can continue for months. The standard approach:

• First assessment: Digital rectal examination and clinical assessment at approximately 8–12 weeks after completing chemoradiation.
• Ongoing observation: If the tumor is shrinking but still present, continued observation with repeat examinations every 4–8 weeks is appropriate. Complete response may take up to 26 weeks (6 months).
• Imaging: PET-CT or MRI may be used to assess response, typically not before 12 weeks after treatment (earlier imaging can show false-positive results due to post-treatment inflammation).

This observation period can be anxiety-provoking for patients and families. Premature intervention — rushing to surgery before the tumor has had time to fully respond — can result in unnecessary permanent colostomies. Patience, with careful monitoring, is the evidence-based approach.

A complete clinical response — no palpable tumor on DRE and no evidence of disease on imaging — is the goal. After achieving complete response, patients enter a structured surveillance program with regular examinations to detect any recurrence early.

When anal cancer persists after chemoradiation (confirmed on biopsy, typically after at least 26 weeks of observation) or recurs after initial complete response, the standard salvage treatment is abdominoperineal resection (APR). This operation removes the anus, rectum, and surrounding tissue, and creates a permanent colostomy.

While APR is a major operation with significant life changes, it can be curative for localized persistent or recurrent disease. Five-year survival after salvage APR ranges from roughly 40–65%, depending on the extent of disease at the time of surgery.

An experienced colorectal surgeon should perform the operation, ideally at a center that performs salvage APR regularly. Flap reconstruction of the perineum (the wound where the anus was removed) is often performed to improve healing, particularly in irradiated tissue.

A permanent colostomy is a significant life change, but patients who have one consistently report that quality of life is better than they expected. A certified wound, ostomy, and continence nurse (WOC nurse) is the single most valuable resource. They provide training, support, and ongoing troubleshooting. The United Ostomy Associations of America (ostomy.org) connects patients with peer support. A pre-operative consultation with a WOC nurse and a stoma site marking are essential before surgery.

• Will you use IMRT for my treatment? How many anal cancer cases do you treat per year?
• What radiation dose are you planning, and over how many weeks?
• What side effects should I expect, and how will skin reactions be managed?
• Will my inguinal lymph nodes be included in the radiation field?
• How will you assess my response, and when?

• Which chemotherapy regimen are you recommending — 5-FU plus mitomycin C, or capecitabine plus mitomycin C?
• What are the specific risks of mitomycin C, and how will my blood counts be monitored?
• If the cancer does not respond completely, what are the next options?
• What clinical trials might I be eligible for?

For metastatic anal squamous cell carcinoma, treatment options include:

• Carboplatin plus paclitaxel: A commonly used first-line chemotherapy combination, based on the InterAACT trial. This has been a standard backbone regimen.
• Cisplatin plus 5-FU: An alternative first-line chemotherapy option.
• Immunotherapy combinations: Adding checkpoint inhibitors to first-line chemotherapy has redefined treatment. The POD1UM-303 trial (NCT04472429) tested retifanlimab plus carboplatin-paclitaxel (leading to the May 2025 FDA approval), and the EA2176 trial (NCT04444921) is evaluating nivolumab with chemotherapy in the first-line metastatic setting.

Ask: "For my metastatic disease, am I a candidate for first-line carboplatin and paclitaxel with retifanlimab, and if not, which single trial should I look at first?" Since immunotherapy added to chemotherapy is now the first-line standard for fit patients, it is worth confirming it was considered.

This is the general logic your team follows, drawn from the NCCN and ESMO guidelines. Your own plan is individualized.

• If your cancer is localized or regional, chemoradiation is the first-line curative treatment, because it cures most patients while preserving the anal sphincter.
• If your disease is metastatic and you are otherwise fit, guidelines consider carboplatin, paclitaxel, and retifanlimab together the preferred first-line option, because adding immunotherapy improved outcomes in the POD1UM-303 trial.
• If immunotherapy is not safe for you (for example, an active autoimmune condition), your team may start with carboplatin and paclitaxel chemotherapy alone.
• If chemoradiation does not fully clear the tumor after an adequate observation period, surgeons consider salvage surgery (APR) rather than more radiation.

Ask: "Given my exact situation, which of these paths am I on, and what is the single most important next step?"

• Nivolumab (Opdivo): Used for metastatic anal squamous cell carcinoma that has progressed after platinum-based chemotherapy, based on the CheckMate 358 trial. Note: nivolumab is not FDA-approved specifically for anal cancer — this is a guideline-based (NCCN) use rather than an anal-cancer label indication. Nivolumab is a PD-1 checkpoint inhibitor that activates the immune system to attack cancer cells.
• Pembrolizumab (Keytruda): Used for previously treated metastatic anal cancer (KEYNOTE-158). Its FDA approval is tumor-agnostic — for tumors that are MSI-H/dMMR or have high tumor mutational burden (TMB-high) — rather than an anal-cancer-specific approval; NCCN supports its use. Also a PD-1 inhibitor, with meaningful and sometimes durable responses.
• Retifanlimab (Zynyz): FDA-approved in May 2025 as the first first-line treatment for inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal, given in combination with carboplatin and paclitaxel, based on the Phase 3 POD1UM-303/InterAACT2 trial (NCT04472429). The European Commission granted the same first-line approval in March 2026.

HPV-driven anal cancers express viral proteins that are foreign to the immune system, making them natural targets for immune recognition. PD-1 checkpoint inhibitors release the brakes on the immune system, allowing T cells to recognize and kill cancer cells displaying these viral antigens. This is why response rates to immunotherapy are generally higher in HPV-positive anal cancer than in many other tumor types.

Immunotherapy side effects differ fundamentally from chemotherapy. Rather than hair loss or nausea, immune-related side effects can affect virtually any organ and are caused by the activated immune system attacking normal tissues. Common immune-related adverse events include skin rashes, diarrhea/colitis, thyroid dysfunction, liver inflammation, and fatigue. Less common but serious events include pneumonitis, myocarditis, and adrenal insufficiency. Most are manageable if recognized early. Report any new symptoms promptly to the medical team.

Combining PD-1 inhibitors with other immunotherapy agents (such as anti-CTLA-4 antibodies like ipilimumab) is being investigated to improve response rates. The EA2176 trial (NCT04444921) is evaluating nivolumab with or without ipilimumab combined with carboplatin-paclitaxel as first-line treatment for metastatic anal cancer.

Adding immunotherapy before or during chemoradiation for localized anal cancer is a major area of investigation. The rationale: the immune system may be more effectively activated when the primary tumor is still present as a source of tumor antigens. Several trials are exploring this approach, including studies combining pembrolizumab or nivolumab with standard chemoradiation.

For patients with early-stage, HPV-positive anal cancer that responds well to treatment, radiation dose de-escalation trials are investigating whether lower doses of radiation (combined with immunotherapy or standard chemotherapy) can maintain high cure rates while reducing long-term side effects. This is analogous to successful de-escalation strategies in HPV-positive oropharyngeal cancer.

Unlike preventive vaccines (which prevent new HPV infections), therapeutic HPV vaccines are designed to stimulate the immune system to attack existing HPV-infected cancer cells. Several candidates are in clinical trials for HPV-related cancers, including anal cancer. These represent a potential future approach but are not yet available outside of clinical trials.

The identifiers below (“NCT” numbers) were confirmed against ClinicalTrials.gov as of July 2026. You can paste any of them into the search box at clinicaltrials.gov to read the full study record, eligibility rules, and participating sites.

• EA2176 (NCT04444921): Carboplatin-paclitaxel with or without nivolumab for first-line metastatic anal cancer.
• POD1UM-303 / InterAACT 2 (NCT04472429): Retifanlimab plus carboplatin-paclitaxel as first-line therapy for inoperable recurrent or metastatic anal squamous cell carcinoma. This trial led to the May 2025 FDA approval of Zynyz.
• POD1UM-202 (NCT03597295): Retifanlimab as a single drug after platinum chemotherapy has stopped working.
• NCI-9673 (NCT02314169): single-arm phase 2 of nivolumab in previously treated metastatic anal cancer — the first trial showing checkpoint immunotherapy is active in this disease (Morris et al., Lancet Oncol 2017). CheckMate 358 is a separate trial (a different registry record) evaluating nivolumab with or without ipilimumab across virus-associated cancers; the two are often cited together but should not be conflated under one identifier.
• KEYNOTE-158 (NCT02628067): Pembrolizumab for previously treated advanced tumors, including anal cancers that are MSI-high or TMB-high.
• RADIANCE (NCT04230759): Standard chemoradiation with or without the immunotherapy durvalumab for locally advanced anal cancer.
• EA2165 (NCT03233711): Nivolumab versus observation after completing chemoradiation for higher-risk stage II–III anal cancer.
• TIRANUS (NCT05661188): Adding tiragolumab and atezolizumab to chemoradiation for localized anal cancer.
• CARACAS (NCT03844256): Mitomycin/capecitabine chemoradiation combined with nivolumab.
• ANCHOR (NCT02135419): Landmark trial showing that treating high-grade anal dysplasia (HSIL) reduces cancer risk by about 57% in people with HIV.

Ask: "Given my exact stage and prior treatment, which one of these trials fits me best, and is it open at a center I can reach?” Search ClinicalTrials.gov for “anal cancer” to find the most current listings.

• Start with the treating center’s clinical trials office. The oncology team knows which trials are open locally.
• Search ClinicalTrials.gov — filter by “anal cancer,” recruiting status, and location.
• Use patient navigation services. The HPV and Anal Cancer Foundation and the National Cancer Institute (1-800-4-CANCER) can help match patients to trials.
• Ask at a second-opinion visit. Major centers may have trials the local team does not.

Huntsman Cancer Institute — Salt Lake City, UT
2000 Circle of Hope Drive, Salt Lake City, UT 84112
Main / new patients: 801-587-7000
NCI-designated Comprehensive Cancer Center. GI cancers program, IMRT radiation therapy, clinical trial access. Anal cancer cases managed through the GI multidisciplinary tumor board.

• MD Anderson Cancer Center (Houston, TX) — 877-632-6789. One of the largest anal cancer treatment programs in the US. Extensive radiation oncology and immunotherapy expertise. Active clinical trial portfolio.
• Memorial Sloan Kettering Cancer Center (New York, NY) — 800-525-2225. Major GI oncology and radiation oncology programs with significant anal cancer experience.
• UCSF Helen Diller Comprehensive Cancer Center (San Francisco, CA) — 415-353-2051. Strong anal cancer and HPV-related malignancy program, particularly serving the LGBTQ+ community.
• Dana-Farber Cancer Institute (Boston, MA) — 877-442-3324. GI oncology program with immunotherapy expertise.
• Mayo Clinic (Rochester, MN) — 507-538-3270. Radiation oncology and colorectal surgery expertise.
• University of Colorado Cancer Center (Aurora, CO) — 720-848-0300. Nearest major academic center to Utah outside Huntsman.

Veterans with anal cancer can receive care through the VA system. VA medical centers with radiation oncology and GI programs can manage the disease. The VA referral system can facilitate access to academic centers when needed.

• VA Salt Lake City Health Care System — 801-582-1565
• VA Greater Los Angeles Healthcare System — 310-478-3711
• Michael E. DeBakey VA Medical Center (Houston, TX) — 713-791-1414

• Princess Margaret Cancer Centre (Toronto, ON) — 416-946-2000. Major radiation oncology program with anal cancer expertise.
• BC Cancer (Vancouver, BC) — 604-877-6000.
• McGill University Health Centre (Montreal, QC) — 514-934-1934.

• The Christie NHS Foundation Trust (Manchester, UK) — Major European center for anal cancer treatment and research. Led the ACT II trial.
• Institut Gustave Roussy (Villejuif, France) — Major European cancer center with GI oncology and radiation expertise.
• Peter MacCallum Cancer Centre (Melbourne, Australia) — Leading Australian cancer center with radiation oncology expertise.

Radiation to the pelvis and perineum causes predictable side effects. Proactive management makes a significant difference:

• Skin care: Keep the treatment area clean and dry. Use recommended barrier creams (such as aquaphor, calendula, or prescribed products). Wear loose, soft clothing. Report any skin breakdown to the radiation team immediately.
• Diarrhea: Follow dietary recommendations (low-residue diet during treatment). Use prescribed anti-diarrheal medications. Stay hydrated.
• Pain management: Perineal pain during treatment is common. Sitz baths, prescribed pain medications, and topical treatments help.
• Nutrition: Consult an oncology dietitian. Maintaining nutrition during treatment improves tolerance and recovery.

Some patients experience long-term effects after chemoradiation that should be discussed openly with the medical team:

• Bowel function changes: Increased frequency, urgency, or occasional incontinence. These often improve over time but may persist. Pelvic floor physical therapy can help significantly.
• Sexual function: Vaginal dryness, stenosis, and dyspareunia in women; erectile dysfunction in men. These are treatable with appropriate support. Vaginal dilator use should be discussed early with women who have received pelvic radiation.
• Pelvic fractures: A risk after pelvic radiation, particularly in postmenopausal women. Bone density monitoring may be appropriate.
• Lymphedema: Swelling in the legs or genital area from radiation to inguinal lymph nodes. Compression garments and lymphedema therapy help.

Anal cancer carries a unique emotional burden because of its location, its association with HPV, and societal discomfort with these topics. Patients frequently report feeling isolated, embarrassed, or unable to discuss their diagnosis openly. These feelings are normal and understandable, but they should not prevent patients from seeking support.

Resources include oncology social workers and psychologists, the HPV and Anal Cancer Foundation (analcancerfoundation.org), online support communities, and peer support programs. Many patients find that connecting with others who have been through anal cancer treatment is profoundly helpful.

Chemoradiation for anal cancer is demanding, and caregivers play a critical role. Key strategies include setting up practical help (meals, rides, household tasks) before the hardest weeks of treatment, understanding the side effect timeline so you can prepare, attending key appointments to hear information together, and accessing caregiver support resources through the cancer center and organizations like the Family Caregiver Alliance (caregiver.org, 800-445-8106).

Anal cancer and its treatment can affect intimacy and sexual health. Open communication between partners is important. The treating team should include discussion of sexual health in follow-up care. Sexual health counselors with oncology experience can help couples navigate these challenges. Treatment-related sexual side effects are medical conditions, not personal failures, and they are treatable.

Anal cancer is one of the genuine success stories in oncology. The fact that a disease previously requiring mutilating surgery can now be cured with chemoradiation while preserving normal function is a remarkable achievement. The addition of immunotherapy for advanced disease has added another meaningful treatment option. The majority of anal cancer patients diagnosed today will be cured and will maintain normal bowel function. For those with metastatic disease, immunotherapy has extended lives in ways that were not possible even a few years ago. There is genuine, well-founded reason for hope.

• Localized (roughly 80–85% five-year survival): The vast majority are cured with chemoradiation. The treatment is demanding but highly effective.
• Regional (roughly 60–70%): Still very treatable. Chemoradiation cures many node-positive patients.
• Metastatic (roughly 30–35%): The most difficult situation, but immunotherapy has improved outcomes meaningfully beyond what chemotherapy alone could achieve. Some patients with metastatic disease achieve durable responses.

• What is the exact stage of my cancer?
• Is this squamous cell carcinoma? Is it HPV-related?
• Do I need HIV testing (if not already done)?
• How many anal cancer patients does this center treat per year?
• Will IMRT be used for my radiation?
• How long will treatment take, and what side effects should I expect?
• Should I get a second opinion?

• What is the realistic chance of cure with chemoradiation?
• How and when will you know if the treatment has worked?
• If the cancer does not respond completely, what are the next steps?
• What are the long-term effects I should prepare for?
• Are there clinical trials I should consider?
• What sexual health support is available?
• Should my family members get HPV vaccination?

You do not have to phrase things perfectly. If it helps, read these verbatim. They are written to get you a specific, actionable answer rather than a vague one.

• Ask: "Is my tumor squamous cell carcinoma, and is it p16 or HPV positive?"
• Ask: "What is my exact TNM stage, and does that put me in the group cured by chemoradiation alone?"
• Ask: "How many anal cancer cases does this center treat each year, and would you recommend a second opinion at a high-volume center?"
• Ask: "Will my radiation plan use IMRT, and will it cover my groin lymph nodes?"
• Ask: "Is mitomycin C part of my plan? I have read it should not be left out of standard curative treatment."
• Ask: "If my tumor is shrinking but still there at the first check, exactly how long will you watch before considering surgery?"
• Ask: "What are the two or three symptoms that mean I should go to the emergency room during treatment?"
• Ask: "Should I be tested for DPD (DPYD) deficiency before starting 5-FU or capecitabine?"
• Ask: "Before radiation starts, should I see someone about fertility preservation or, for women, moving my ovaries out of the radiation field?"
• Ask: "Can you connect me today with a financial counselor and a social worker, and start any assistance applications now?"

These are conversation starters, not scripts your team must answer a certain way. The goal is a clear, individualized plan — per the NCCN Anal Carcinoma Guidelines, decisions are made with your multidisciplinary team.

• The treating center’s financial counseling office. Engage them early for insurance navigation, copay assistance, and payment plans.
• The oncology social worker. Connects families to assistance, transportation, and lodging resources.

• Patient Advocate Foundation — 800-532-5274. patientadvocate.org
• CancerCare — 800-813-4673. cancercare.org
• HealthWell Foundation — 800-675-8416. healthwellfoundation.org
• PAN Foundation — 866-316-7263. panfoundation.org
• Family Reach — familyreach.org
• NeedyMeds — 800-503-6897. needymeds.org

Costs vary widely by insurance, but here is an orientation to the drug side of anal cancer care (US prices, as of July 2026). The chemotherapy used with radiation is generic and relatively inexpensive; the biggest costs are the radiation course itself and, for advanced disease, immunotherapy.

• The chemoradiation drugs are generic. Generic oral capecitabine runs about $50 for a full 84-tablet bottle of 500 mg tablets with a pharmacy discount card, versus roughly $280 at full retail (GoodRx estimate, June 2026). Generic injectable 5-FU is roughly $65–$145 for four 10-mL vials, and generic mitomycin is roughly $100 per 20 mg vial (GoodRx/SingleCare estimates, 2026).
• How the billing splits. Drugs given by vein in the clinic — 5-FU, mitomycin, carboplatin/paclitaxel, and the immunotherapy retifanlimab (Zynyz) — are billed under your medical benefit (Medicare Part B or the medical side of commercial insurance), not the pharmacy counter. Oral capecitabine runs through your pharmacy benefit (Medicare Part D). This matters because your out-of-pocket share is calculated differently for each.
• Immunotherapy is the high-cost item. Retifanlimab and other checkpoint inhibitors are branded biologics costing thousands of dollars per dose. Most of that is handled through your medical benefit, and the manufacturer's patient-assistance program (IncyteCARES for Zynyz) plus copay-assistance foundations can cover much or all of the patient share for eligible people.
• Prevention for your family. The Gardasil 9 HPV vaccine has a manufacturer list price of $328.34 per dose (as of August 2025), but most private plans must cover recommended HPV vaccination with no copay, and the federal Vaccines for Children program covers eligible children at no cost.

Coverage path: start with the treating center's financial counselor and oncology social worker, then apply to the copay-assistance foundations listed above (PAN Foundation, HealthWell, CancerCare) and the drug manufacturer's assistance program. Engage them before the first infusion, not after the first bill.

These are orientation figures, not a bill. Actual amounts depend on your insurance, your center, and negotiated rates. Sources and dates are named so you can check them. “List price” is the sticker price before insurance; your out-of-pocket share is usually far lower.

How out-of-pocket costs actually land. A few anchors so the numbers are not abstract. In 2026, standard Medicare Part B pays 80% of the approved amount for clinic-infused drugs and leaves you responsible for the other 20% unless you have supplemental coverage — so a branded immunotherapy dose with a list price of roughly $10,000 could carry a coinsurance share near $2,000 per dose before any assistance. On the Part D (pharmacy) side, the Inflation Reduction Act caps a Medicare beneficiary's total out-of-pocket drug spending at $2,100 for the year in 2026 (the cap started at $2,000 in 2025 and is indexed annually), which protects patients on oral capecitabine. Commercial plans typically cap annual out-of-pocket around $9,200 for an individual in 2025–2026. Copay-assistance foundations and the manufacturer program (IncyteCARES for Zynyz) frequently reduce the immunotherapy share toward $0 for eligible patients.

Ask the financial counselor: "Can you give me a written good-faith cost estimate for the whole chemoradiation course, tell me what my out-of-pocket maximum is, and start the copay-assistance and manufacturer applications today?" Under the federal No Surprises Act, uninsured and self-pay patients are entitled to a good-faith estimate in advance.

• HPV and Anal Cancer Foundation — analcancerfoundation.org. Education, support, awareness for anal cancer patients.
• United Ostomy Associations of America — ostomy.org. For patients who require colostomy.
• American Cancer Society — 800-227-2345. cancer.org. General cancer support and resources.
• National Cancer Institute — 1-800-4-CANCER. cancer.gov. Information and trial search.

Retifanlimab (Zynyz) was approved by the FDA in May 2025 as the first first-line therapy for inoperable recurrent or metastatic anal squamous cell carcinoma, used in combination with carboplatin and paclitaxel (via POD1UM-303); the European Commission granted the same first-line approval in March 2026. Pembrolizumab is available for anal cancers that are MSI-high or TMB-high through its tissue-agnostic approvals (KEYNOTE-158), and nivolumab has been studied in this setting (CheckMate 358). Standard chemoradiation agents (5-FU, mitomycin C, capecitabine) have long-standing approvals. NCCN Anal Carcinoma Guidelines are the primary clinical reference.

Nivolumab and pembrolizumab are available in Europe for various indications. Access for anal cancer specifically varies by country and funding mechanisms. The ACT II trial, which contributed key evidence for anal cancer chemoradiation, was led by UK investigators. ESMO guidelines cover anal cancer management and may differ in nuance from NCCN.

Anal cancer is relatively uncommon in Japan compared to Western countries. Standard chemoradiation protocols are used. Nivolumab and pembrolizumab are approved in Japan for multiple tumor types, with availability for anal cancer through specific indications or clinical trials.

Standard chemoradiation is widely available. Pembrolizumab and nivolumab are available through provincial formularies for various indications. Access for anal cancer specifically may require special authorization. Canadian guidelines generally align with NCCN and ESMO.

• Cisplatin replacing mitomycin C in chemoradiation FAILED
  The RTOG 98-11 trial tested whether cisplatin could replace mitomycin C as the chemotherapy partner during radiation. The cisplatin arm showed inferior disease-free survival and colostomy-free survival. Mitomycin C remains the standard despite its toxicity.
• Neoadjuvant chemotherapy before chemoradiation FAILED
  The ACCORD 03 trial tested induction chemotherapy (cisplatin plus 5-FU) before chemoradiation for locally advanced anal cancer. No improvement in complete response rate or colostomy-free survival was demonstrated.
• Maintenance chemotherapy after chemoradiation FAILED
  The ACT II trial tested maintenance cisplatin plus 5-FU after completing chemoradiation. No benefit in response or survival was found. Maintenance chemotherapy is not recommended after definitive chemoradiation.
• Primary surgery (APR) as initial treatment DE-ADOPTED
  Before the Nigro protocol, APR with permanent colostomy was the standard treatment. Chemoradiation was shown to achieve equivalent cure rates while preserving the sphincter. Primary surgery is now reserved only for salvage after failed chemoradiation or for very small anal margin tumors amenable to local excision.

• Abdominoperineal resection (APR) — surgical removal of the anus, rectum, and surrounding tissue; creates a permanent colostomy. Used as salvage for persistent or recurrent anal cancer.
• Anal canal — the short passage at the end of the digestive tract where stool exits the body.
• Anal margin — the skin surrounding the anal opening.
• Chemoradiation — combination of radiation therapy and chemotherapy given simultaneously; the standard curative treatment for anal cancer.
• Checkpoint inhibitor — a type of immunotherapy drug that activates the immune system to recognize and attack cancer cells.
• Colostomy — a surgically created opening on the abdomen through which stool passes into a pouch.
• DRE — digital rectal examination; a key part of anal cancer assessment.
• HSIL — high-grade squamous intraepithelial lesion; a precancerous change in the anal canal that can progress to cancer if untreated.
• HPV — human papillomavirus; a common virus that causes the vast majority of anal squamous cell carcinomas.
• HRA — high-resolution anoscopy; a procedure to examine the anal canal and identify precancerous or cancerous changes.

• IMRT — intensity-modulated radiation therapy; the standard radiation technique for anal cancer that reduces side effects.
• Immunotherapy — treatment that activates the immune system to fight cancer; checkpoint inhibitors are the main type used in anal cancer.
• Mitomycin C — a chemotherapy drug given with radiation as part of the standard Nigro protocol for anal cancer.
• Nigro protocol — the standard chemoradiation regimen for anal cancer, combining radiation with 5-FU and mitomycin C.
• Nivolumab (Opdivo) — a PD-1 checkpoint inhibitor used for metastatic anal cancer (NCCN-recommended; not an anal-cancer-specific FDA approval).
• p16 — a protein that serves as a marker of HPV-driven cancer when detected by immunohistochemistry.
• PD-1 — a protein on immune cells that cancer uses to hide from the immune system; blocked by nivolumab and pembrolizumab.
• Pembrolizumab (Keytruda) — a PD-1 checkpoint inhibitor used for metastatic anal cancer (FDA approval is tumor-agnostic, for MSI-H/dMMR or TMB-high tumors).
• Retifanlimab (Zynyz) — a PD-1 checkpoint inhibitor approved as first-line therapy (with carboplatin-paclitaxel) for metastatic anal cancer (FDA May 2025; EU March 2026).
• Salvage surgery — surgery performed when chemoradiation does not eliminate the cancer; typically APR.
• Squamous cell carcinoma — the most common type of anal cancer, arising from the lining cells of the anal canal.

Guidelines:

• NCCN Clinical Practice Guidelines — Anal Carcinoma (current version)
• ESMO Clinical Practice Guidelines for anal cancer

Landmark trials referenced in this guide:

If you or your doctor want to read the original evidence, these are the peer-reviewed papers and guidelines this guide draws on. Each “PMID” number can be searched directly on PubMed (pubmed.ncbi.nlm.nih.gov). All were confirmed against PubMed and ClinicalTrials.gov in July 2026.

• Curative chemoradiation, RTOG 98-11 trial — Gunderson LL et al, Journal of Clinical Oncology, 2012 (PMID 23150707). Long-term results showing 5-FU plus mitomycin C with radiation is superior to cisplatin-based treatment. Trial record NCT00003596.
• Mitomycin vs. cisplatin and maintenance, ACT II trial — James RD et al, Lancet Oncology, 2013 (PMID 23578724). Confirmed mitomycin as the standard and that maintenance chemotherapy adds no benefit.
• Chemoradiation vs. radiation alone, EORTC 22861 trial — Bartelink H et al, Journal of Clinical Oncology, 1997 (PMID 9164216). Established that adding chemotherapy to radiation improves local control and colostomy-free survival.
• Induction chemotherapy, ACCORD-03 trial — Peiffert D et al, Journal of Clinical Oncology, 2012 (PMID 22529257). Showed no benefit from chemotherapy before chemoradiation.
• IMRT technique, RTOG 0529 trial — Kachnic LA et al, International Journal of Radiation Oncology, Biology, Physics, 2013 (PMID 23154075). Established dose-painted IMRT as the standard radiation technique. Trial record NCT00423293.
• First-line metastatic chemotherapy, InterAACT trial — Rao S et al, Journal of Clinical Oncology, 2020 (PMID 32530769). Established carboplatin-paclitaxel as the preferred backbone over cisplatin-5-FU.
• Nivolumab immunotherapy, NCI-9673 study — Morris VK et al, Lancet Oncology, 2017 (PMID 28223062). First trial showing checkpoint immunotherapy is active in previously treated metastatic anal cancer. Trial record NCT02314169.
• Preventing cancer by treating HSIL, ANCHOR trial — Palefsky JM et al, New England Journal of Medicine, 2022 (PMID 35704479). Showed treating precancerous anal lesions cuts cancer risk by about 57% in people with HIV. Trial record NCT02135419.
• Retifanlimab FDA prescribing information (Zynyz) — Incyte Corporation; first-line combination and post-platinum single-agent indications for anal squamous cell carcinoma; FDA approval May 2025 (verified via openFDA, July 2026).
• NCCN Clinical Practice Guidelines in Oncology — Anal Carcinoma (v2.2025) and the ESMO anal cancer guideline — the primary standards this guide follows for dosing and sequencing.

• HPV and Anal Cancer Foundation (analcancerfoundation.org) — Education, support, awareness for anal cancer patients.
• PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research.
• ClinicalTrials.gov (clinicaltrials.gov) — Official U.S. registry of clinical trials.
• National Cancer Institute (cancer.gov) — Information and trial search (1-800-4-CANCER).
• American Cancer Society (cancer.org) — 800-227-2345. General cancer support.